PARP抑制剂抗肿瘤治疗研究进展  

Poly ADP-ribose polymerase inhibitors in cancer therapy

作　　者：马强[1] 郝吉庆[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤内科,合肥230032

出　　处：《国际肿瘤学杂志》2012年第11期837-839,共3页Journal of International Oncology

摘　　要：聚ADP核糖聚合酶（PARP）在DNA损伤修复、维持基因组稳定性方面起着重要作用。因此PARP抑制剂能够抑制肿瘤细胞DNA损伤修复、增强肿瘤细胞DNA对损伤因素的敏感性。近年来PARP抑制剂的研究受到了越来越多的关注。PARP抑制剂单药可以在具有某些基因突变的肿瘤中发挥合成致死作用，与化疗或放疗联合能够增加肿瘤细胞对化疗或放疗的敏感性。PARP抑制剂有望在肿瘤治疗领域中发挥重要作用。Poly ADP ribose polymerases （PARP） play an important role in DNA damage repair and genome stability. So, PARP inhibitors can inhibit the DNA damage repairing of tumor cells and enhance the sensitivity of the DNA of tumor ceils to damage factors. In recent years, PARP inhibitors have been more and more concerned. PARP inhibitors can kill tumor cells with certain genetic mutations alone by synthetic lethal effect. In addition, PARP inhibitors in combination with chemotherapy or radiotherapy can increase the sensi tivity of tumor cells to the chemotherapy or radiotherapy. PARP inhibitors are expected to play an important role in cancer therapy.

关 键 词：聚ADP核糖聚合酶类 酶抑制剂 DNA损伤 DNA修复酶类 肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]